Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung.

[1]  W. Jiao,et al.  Predictive value of a prognostic model based on pathologic features in lung invasive adenocarcinoma. , 2019, Lung cancer.

[2]  Qifan Yin,et al.  Prognostic Impact of Tumor Spread Through Air Spaces in Non-small Cell Lung Cancers: a Meta-Analysis Including 3564 Patients , 2019, Pathology & Oncology Research.

[3]  David R. Jones,et al.  Procedure‐Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (≤2 cm) Lung Adenocarcinoma: An International Cohort Analysis , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[4]  Y. Akagi,et al.  Tumor Spread Through Air Spaces Identifies a Distinct Subgroup With Poor Prognosis in Surgically Resected Lung Pleomorphic Carcinoma , 2018, Chest.

[5]  Y. Mao,et al.  Spread through air spaces predicts a worse survival in patients with stage I adenocarcinomas >2 cm after radical lobectomy. , 2018, Journal of thoracic disease.

[6]  Y. Maehara,et al.  Significance of Spread Through Air Spaces in Resected Pathological Stage I Lung Adenocarcinoma. , 2018, The Annals of thoracic surgery.

[7]  S. Shiono,et al.  Tumor spread through air spaces is a useful predictor of recurrence and prognosis in stage I lung squamous cell carcinoma, but not in stage II and III. , 2018, Lung cancer.

[8]  Sukki Cho,et al.  Prognostic stratification model for patients with stage I non-small cell lung cancer adenocarcinoma treated with surgical resection without adjuvant therapies using metabolic features measured on F-18 FDG PET and postoperative pathologic factors. , 2018, Lung cancer.

[9]  Sukki Cho,et al.  Pathological prognostic factors of recurrence in early stage lung adenocarcinoma , 2018, ANZ journal of surgery.

[10]  Y. Maehara,et al.  High Frequency of Spread Through Air Spaces in Resected Small Cell Lung Cancer. , 2018, Anticancer research.

[11]  R. Haba,et al.  Tumor Spread Through Air Spaces Is an Independent Predictor of Recurrence-free Survival in Patients With Resected Lung Squamous Cell Carcinoma , 2017, The American journal of surgical pathology.

[12]  V. Rusch,et al.  Lung cancer — major changes in the American Joint Committee on Cancer eighth edition cancer staging manual , 2017, CA: a cancer journal for clinicians.

[13]  W. Travis,et al.  Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer–Specific Death in Squamous Cell Carcinoma , 2017, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[14]  David R. Jones,et al.  Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  I. Yoshino,et al.  Impact of free tumor clusters on prognosis after resection of pulmonary adenocarcinoma. , 2016, The Journal of thoracic and cardiovascular surgery.

[16]  A. Warth,et al.  Clinical Relevance of Different Papillary Growth Patterns of Pulmonary Adenocarcinoma , 2016, The American journal of surgical pathology.

[17]  G. Giaccone,et al.  Treatment of Small-Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians Guideline. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  A. Warth,et al.  Prognostic Impact of Intra-alveolar Tumor Spread in Pulmonary Adenocarcinoma , 2015, The American journal of surgical pathology.

[19]  David R. Jones,et al.  Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[20]  L. Marks,et al.  Lung , 2013, ALERT • Adverse Late Effects of Cancer Treatment.

[21]  J. Dignam,et al.  The Use and Interpretation of Competing Risks Regression Models , 2012, Clinical Cancer Research.

[22]  C. Sima,et al.  Neoadjuvant and adjuvant chemotherapy in resected pulmonary large cell neuroendocrine carcinomas: a single institution experience. , 2011, The Annals of thoracic surgery.

[23]  W. Travis.  Advances in neuroendocrine lung tumors. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[24]  William Pao,et al.  Comprehensive Histologic Assessment Helps to Differentiate Multiple Lung Primary Nonsmall Cell Carcinomas From Metastases , 2009, The American journal of surgical pathology.

[25]  Irvin M Modlin,et al.  Bronchopulmonary neuroendocrine tumors , 2008, Cancer.

[26]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  L. Fabbri,et al.  Role of Chemotherapy and the Receptor Tyrosine Kinases KIT, PDGFRα, PDGFRβ, and Met in Large-Cell Neuroendocrine Carcinoma of the Lung , 2005 .

[28]  M. Sheppard,et al.  Small Cell Lung Carcinoma (SCLC): A Clinicopathologic Study of 100 Cases With Surgical Specimens , 2002, The American journal of surgical pathology.

[29]  J. Olsen,et al.  Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. , 2002, Lung cancer.

[30]  Qin Huang,et al.  Pulmonary neuroendocrine carcinomas. A review of 234 cases and a statistical analysis of 50 cases treated at one institution using a simple clinicopathologic classification. , 2002, Archives of pathology & laboratory medicine.

[31]  R. Steele,et al.  Pulmonary atypical carcinoid: predictors of survival in 106 cases. , 2000, Human pathology.

[32]  Robert Gray,et al.  A Proportional Hazards Model for the Subdistribution of a Competing Risk , 1999 .

[33]  W T McGivney,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[34]  D. Carter,et al.  Tumors of the lower respiratory tract , 1996 .

[35]  H. Liu,et al.  Treatment of small cell lung cancer. , 1991, Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih.

[36]  Y. Kimula,et al.  Bronchial carcinoid with multiple aerogenous implanted foci , 1987, Journal of surgical oncology.

[37]  David R. Jones,et al.  Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)‐Positive T1 Lung Adenocarcinoma: A Propensity Score–Matched Analysis , 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[38]  W. Travis.  WHO classification of tumours of the lung, pleura, thymus and heart , 2015 .

[39]  R. Gray.  A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk , 1988 .

[40]  A. Liebow.  Tumors of the lower respiratory tract , 1952 .